Clinical Trials Logo

Psychotic Disorders clinical trials

View clinical trials related to Psychotic Disorders.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06219265 Active, not recruiting - Clinical trials for Severe Mental Disorder

Neuropsychological and Electrophysiological Effects of Dance Therapy With People With Severe Mental Disorders

Start date: September 12, 2023
Phase: N/A
Study type: Interventional

A single-centre prospective randomised controlled trial will be conducted with a minimum of 47 patients with severe mental disorder (SMD) who will be randomly assigned into two groups, 1 intervention group receiving dance therapy (n=26) and 1 control group who will not receive any intervention or added treatment apart from continuing with their usual treatment (pharmacological), but will not receive intervention with dance therapy (n=21). In summary, the groups are: - Experimental group (n=26): people with SMD receiving dance therapy. - Control group (n=21): people with SMD who do not receive the dance therapy intervention but do receive their usual pharmacological treatment. Tests will be administered before the start of the study and at the end of the study, as well as 3 months after the end of the study in order to compare the results between groups.

NCT ID: NCT06192602 Active, not recruiting - Psychotic Disorders Clinical Trials

Effects of an Acceptance-based Medication Adherence Therapy for Recent-onset Psychosis

AIM_AT
Start date: March 1, 2022
Phase: N/A
Study type: Interventional

This randomized controlled trial aimed to examine the effectiveness of a 10-session acceptance-based, insight-inducing medication adherence therapy (AIM-AT) program for recent-onset psychosis (in addition to usual care) over a 12-month follow-up (i.e., at immediate, 6-month, and 12-month post-intervention).

NCT ID: NCT06160869 Active, not recruiting - Psychosis Clinical Trials

Effect of Acceptance and Commitment Therapy on Psychotic Severity

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

Our study aims to assess the efficacy of Acceptance and Commitment Therapy on psychotic severity among Inpatients with primary psychosis: A Randomized Controlled Trial.

NCT ID: NCT06132373 Active, not recruiting - Clinical trials for Mental Disorder of Infancy, Childhood, or Adolescence (Diagnosis)

Assessing Implementation of Delivering Community-based, Peer-led Interventions for Mental Health Problems Among Youth in Eldoret, Kenya

Husisha
Start date: June 27, 2023
Phase: N/A
Study type: Interventional

Introduction: Mental health disorders are a leading cause of disability among youth globally, and this has been worsened by the COVID-19 pandemic. In low and middle-income countries like Kenya and in rural Indiana, there is an enormous treatment gap for youth mental disorders due to limited mental health care resources. Goals: The purpose of this project is to examine the implementation of community-based, peer-led management of mental health care screening, and treatment for adolescents in Eldoret, Kenya using the REAIM framework. Methods: We shall conduct a one-week training to peer-mentors on screening for common mental health problems using the SDQ, PHQ-9, GAD-7, and YTP and treating adolescents who screen positive using a 5 session Problem Solving Treatment (PST), an evidence-based treatment for common youth mental health problems. We will then select five of the peers to deliver the intervention under the supervision of the study team at the largest community-based youth drop-in center, Family Health Options Kenya (FHOK), in Eldoret, where the peers already provide mentorship to adolescents. We will use the REAIM Framework to assess the reach, effectiveness, adoption, implementation, and maintenance of this intervention.

NCT ID: NCT05872555 Active, not recruiting - Psychotic Disorders Clinical Trials

Side Effects of Psychiatric Medications - a Nested Case Control Cohort Historical Prospective Study

Start date: March 26, 2023
Phase:
Study type: Observational

The study is designed to fill in the gaps in current knowledge by providing a more inclusive and comprehensive understanding of the potential associations between different psychiatric medications, including antipsychotics (APs), Antidepressants, Benzodiazepines and mood stabilizers, and negative outcomes, as previous research has often been limited to data from clinical trials. The primary objectives of the study include assessing the association between different psychiatric medications and long-term major negative medical conditions and events. Additionally, the study aims to assess the association between different psychiatric medications and long-term negative metabolic events such as diabetes, obesity, hypertension and hypercholesterolemia. This study aims to investigate the potential long-term negative effects of different psychiatric medications on patients with schizophrenia, schizoaffective disorder, depression, bipolar disorder and dementia, patients with other diagnoses, as well as patients receiving different psychiatric medications who do not have a psychiatric diagnosis. The study will be done using data from the Clalit Health Services (CHS) database, which is the largest provider of health insurance in Israel, serving approximately 55% of the population. This database provides access to all diagnoses and blood tests for the duration of the study, which allows for accurate tracking of patient outcomes over time. Inclusion criteria include being diagnosed with schizophrenia/schizoaffective disorder/bipolar disorder/depression, dementia, other psychiatric diagnoses, and/or patients receiving these medications who do not have a psychiatric diagnosis, and use psychiatric medications, including antipsychotics/antidepressants/mood stabilizers/benzodiazepines as registered in the Clalit database. having first prescription of psychiatric medication between 2001 and 2024. The study will look at those patients included and will follow them using the CHS database to assess these different medical and or metabolic side-effects and the appearance of major negative and major metabolic events, as well as abnormal metabolic measurements.

NCT ID: NCT05746494 Active, not recruiting - Schizophrenia Clinical Trials

The Efficacy of Neural Stimulation in Individuals With Schizophrenia

Start date: November 21, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to understand the relationship between psychotic symptoms and social functioning in individuals with schizophrenia spectrum disorders. Our goal is to determine whether stimulating the brain using transcranial Direct Current Stimulation (tDCS) can improve symptoms and daily functioning.

NCT ID: NCT05726617 Active, not recruiting - Psychotic Disorders Clinical Trials

Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders

Avatar-CUD
Start date: September 24, 2019
Phase: N/A
Study type: Interventional

This is a proof-of-concept of a new Virtual Reality (VR) Avatar Intervention for Cannabis Use Disorders (CUD) in patients with psychotic disorders and/or mood disorders. The primary outcomes are reductions in cannabis use, cannabis use disorder severity, and increased quality of life.

NCT ID: NCT05703711 Active, not recruiting - Depression Clinical Trials

Combining mHealth and Nurse-delivered Care to Improve the Outcomes of People With Serious Mental Illness in West Africa

Start date: June 30, 2023
Phase: N/A
Study type: Interventional

In West Africa, most people with serious mental illness receive care from traditional or faith healers at prayer camps. The stepped-wedge cluster randomized trial aims to evaluate the effectiveness of a dual-pronged intervention package comprised of a mobile health program designed to train healers to deliver evidence-based psychosocial interventions combined with pharmacotherapy delivered directly to the patients at their prayer camps via a visiting nurse in Ghana.

NCT ID: NCT05660070 Active, not recruiting - Schizophrenia Clinical Trials

Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness

mSITE
Start date: July 1, 2022
Phase: N/A
Study type: Interventional

This open trial will test a new technology-supported blended intervention, mobile Social Interaction Therapy by Exposure (mSITE), that targets social engagement in consumers with serious mental illness.

NCT ID: NCT05658510 Active, not recruiting - Schizophrenia Clinical Trials

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

Start date: November 21, 2022
Phase: Phase 3
Study type: Interventional

In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.